Low-dose interleukin-2 (IL-2) shows potential for treating autoimmune disorders by expanding regulatory T cells (Treg), but therapeutic utility is limited by short half-life and off-target effects. Here, we describe the molecular design, nonclinical development, and first-in-human study of MHS552, an IL-2 mutein-engraf...
Igor Radanović, Michael DiDonato, A. Meijs et al.· Nature Communications· 0 citations
Generative-AI has raised uncertainties for New Zealand creators seeking copyright protection
under the Copyright Act 1994. As AI software becomes increasingly integrated into creative
practice, it is unclear when AI-assisted and AI-generated works will qualify for copyright
protection and how existing principles of aut...
Hannah Morgan· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.